{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:08:21Z","timestamp":1792789701409,"version":"4.5.0"},"reference-count":104,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"name":"Bayer HealthCare Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The prevention and treatment of venous thromboembolism (VTE) remains a clinical challenge, primarily owing to drawbacks associated with the use of heparins and vitamin K antagonists (VKAs). These and other factors, including a growing elderly population, mean that VTE presents a continuing burden to patients and physicians. Anticoagulant therapy is a fundamental approach for VTE management. Non- VKA oral anticoagulants, including the factor Xa inhibitors apixaban, edoxaban and rivaroxaban, and the thrombin inhibitor dabigatran, have been studied in phase III trials across a spectrum of thromboembolic disorders. These agents offer simplified care, with similar or improved efficacy and safety outcomes compared with heparins and vitamin K antagonists. There are several factors a physician must consider when prescribing an anticoagulant. An important consideration with all anticoagulant use is bleeding risk, especially in high-risk groups such as the elderly or those with renal impairment or cancer. In orthopaedic patients, other risks include a need for surgical revision or blood transfusion, or wound complications. Therefore, the clinical benefits of an anticoagulant should ideally be balanced with any risks associated with the therapy. Quantitative benefit\u2013risk assessments are lacking, and owing to differences in trial design the non-VKA oral anticoagulants cannot be compared directly. Based on trial and \u201creallife\u201d data, this review will summarise the clinical data for the non-VKA oral anticoagulants in the prevention and treatment of VTE, focusing on the balance between the benefits and risks of anticoagulation with these drugs, and their potential impact on VTE management.<\/jats:p>","DOI":"10.1160\/th14-06-0484","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T09:06:44Z","timestamp":1413450404000},"page":"231-246","source":"Crossref","is-referenced-by-count":34,"title":["Benefit\u2013risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism"],"prefix":"10.1160","volume":"113","author":[{"given":"Walter","family":"Ageno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"10.1160\/TH14-06-0484-1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61904-1"},{"key":"10.1160\/TH14-06-0484-2","doi-asserted-by":"crossref","unstructured":"Liu X, et al. Epidemiology and mortality of venous thromboembolism across patient populations: a systematic literature review. Value Health 2013; 16: A272: Abstract PCV5","DOI":"10.1016\/j.jval.2013.03.1407"},{"key":"10.1160\/TH14-06-0484-3","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.04.007"},{"key":"10.1160\/TH14-06-0484-4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032274"},{"key":"10.1160\/TH14-06-0484-5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2404"},{"key":"10.1160\/TH14-06-0484-6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301"},{"key":"10.1160\/TH14-06-0484-7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01414.x"},{"key":"10.1160\/TH14-06-0484-8","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1510-z"},{"key":"10.1160\/TH14-06-0484-9","unstructured":"Bayer Pharma AG. Xarelto\u00ae (rivaroxaban) Summary of Product Characteristics. 2014. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. Accessed July 15, 2014"},{"key":"10.1160\/TH14-06-0484-10","unstructured":"Bristol-Myers Squibb, Pfizer EEIG. Eliquis\u00ae (apixaban) Summary of Product Characteristics. 2013. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf. Accessed July 15, 2014"},{"key":"10.1160\/TH14-06-0484-11","unstructured":"Boehringer Ingelheim International GmbH. Pradaxa\u00ae (dabigatran etexilate) Summary of Product Characteristics. 2014. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf. Accessed July 14, 2014"},{"key":"10.1160\/TH14-06-0484-12","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.046888"},{"key":"10.1160\/TH14-06-0484-13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000078469.07362.E6"},{"key":"10.1160\/TH14-06-0484-14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"10.1160\/TH14-06-0484-15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"10.1160\/TH14-06-0484-16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"10.1160\/TH14-06-0484-17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"10.1160\/TH14-06-0484-18","doi-asserted-by":"publisher","DOI":"10.1016\/S0883-5403(09)00329-5"},{"key":"10.1160\/TH14-06-0484-19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62125-5"},{"key":"10.1160\/TH14-06-0484-20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006885"},{"key":"10.1160\/TH14-06-0484-21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810773"},{"key":"10.1160\/TH14-06-0484-22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02748.x"},{"key":"10.1160\/TH14-06-0484-23","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0679"},{"key":"10.1160\/TH14-06-0484-24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61445-7"},{"key":"10.1160\/TH14-06-0484-25","doi-asserted-by":"crossref","unstructured":"Fuji T, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 3320","DOI":"10.1182\/blood.V116.21.3320.3320"},{"key":"10.1160\/TH14-06-0484-26","unstructured":"Fuji T, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. 21st International Congress on Thrombosis. Milan, Italy, 6-9 July 2010; Abstract OC297"},{"key":"10.1160\/TH14-06-0484-27","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-07-0482"},{"key":"10.1160\/TH14-06-0484-28","doi-asserted-by":"publisher","DOI":"10.1177\/1076029612437579"},{"key":"10.1160\/TH14-06-0484-29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3675"},{"key":"10.1160\/TH14-06-0484-30","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S54714"},{"key":"10.1160\/TH14-06-0484-31","doi-asserted-by":"publisher","DOI":"10.2165\/11587290-000000000-00000"},{"key":"10.1160\/TH14-06-0484-32","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-09-0601"},{"key":"10.1160\/TH14-06-0484-33","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.009"},{"key":"10.1160\/TH14-06-0484-34","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/05\/WC500127902.pdf. Accessed August 6, 2014"},{"key":"10.1160\/TH14-06-0484-35","doi-asserted-by":"publisher","DOI":"10.5482\/HAMO-12-05-0004"},{"key":"10.1160\/TH14-06-0484-36","doi-asserted-by":"crossref","unstructured":"Rosencher N, et al. Real-world study of dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients: favourable safety profile in subgroups with different BMI, renal function and age. Blood (ASH Annual Meeting Abstracts) 2012; 120: Abstract 1160","DOI":"10.1182\/blood.V120.21.1160.1160"},{"key":"10.1160\/TH14-06-0484-37","doi-asserted-by":"publisher","DOI":"10.2174\/1874325001105010395"},{"key":"10.1160\/TH14-06-0484-38","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-10-14"},{"key":"10.1160\/TH14-06-0484-39","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-08-0666"},{"key":"10.1160\/TH14-06-0484-40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04877.x"},{"key":"10.1160\/TH14-06-0484-41","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-07-0510"},{"key":"10.1160\/TH14-06-0484-42","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.9.963"},{"key":"10.1160\/TH14-06-0484-43","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2296"},{"key":"10.1160\/TH14-06-0484-44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411103"},{"key":"10.1160\/TH14-06-0484-45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38733.466748.7C"},{"key":"10.1160\/TH14-06-0484-46","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.01.011"},{"key":"10.1160\/TH14-06-0484-47","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2993"},{"key":"10.1160\/TH14-06-0484-48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111096"},{"key":"10.1160\/TH14-06-0484-49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110899"},{"key":"10.1160\/TH14-06-0484-50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2012.10.001"},{"key":"10.1160\/TH14-06-0484-51","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-11-200312020-00007"},{"key":"10.1160\/TH14-06-0484-52","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12148"},{"key":"10.1160\/TH14-06-0484-53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"10.1160\/TH14-06-0484-54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004450"},{"key":"10.1160\/TH14-06-0484-55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"10.1160\/TH14-06-0484-56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638"},{"key":"10.1160\/TH14-06-0484-57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"10.1160\/TH14-06-0484-58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"10.1160\/TH14-06-0484-59","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-21"},{"key":"10.1160\/TH14-06-0484-60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7498"},{"key":"10.1160\/TH14-06-0484-61","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12485"},{"key":"10.1160\/TH14-06-0484-62","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.035"},{"key":"10.1160\/TH14-06-0484-63","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12486"},{"key":"10.1160\/TH14-06-0484-64","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.761"},{"key":"10.1160\/TH14-06-0484-65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d3036"},{"key":"10.1160\/TH14-06-0484-66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702063360601"},{"key":"10.1160\/TH14-06-0484-67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113697"},{"key":"10.1160\/TH14-06-0484-68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207541"},{"key":"10.1160\/TH14-06-0484-69","unstructured":"Beyer-Westendorf J, et al. Treatment of acute VTE with rivaroxaban. Updated results of the prospective Dresden NOAC registry (NCT01588119). J Thromb Haemost 2013; 11: 314-315: Abstract PA 1.10-5"},{"key":"10.1160\/TH14-06-0484-70","unstructured":"Beyer-Westendorf J, et al. Pattern and management of bleeding complications with new oral anticoagulants. Results of the prospective Dresden NOAC Registry (NCT01588119). J Thromb Haemost 2013; 11: 774: Abstract PB 3.26-6"},{"key":"10.1160\/TH14-06-0484-71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04507.x"},{"key":"10.1160\/TH14-06-0484-72","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.6.681"},{"key":"10.1160\/TH14-06-0484-73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064247"},{"key":"10.1160\/TH14-06-0484-74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025313"},{"key":"10.1160\/TH14-06-0484-75","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2297"},{"key":"10.1160\/TH14-06-0484-76","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.10.015"},{"key":"10.1160\/TH14-06-0484-77","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn208"},{"key":"10.1160\/TH14-06-0484-78","unstructured":"Beyer-Westendorf J, et al. Chronic VTE treatment VTE with rivaroxaban. Updated results of the prospective Dresden NOAC registry (NCT01588119). J Thromb Haemost 2013; 11: 439: Abstract PA 3.19-2"},{"key":"10.1160\/TH14-06-0484-79","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.726232"},{"key":"10.1160\/TH14-06-0484-80","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12324"},{"key":"10.1160\/TH14-06-0484-81","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6977.452"},{"key":"10.1160\/TH14-06-0484-82","doi-asserted-by":"crossref","unstructured":"Prins M, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood (ASH Annual Meeting Abstracts) 2012; 120: Abstract 1163","DOI":"10.1182\/blood.V120.21.1163.1163"},{"key":"10.1160\/TH14-06-0484-83","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-03-0243"},{"key":"10.1160\/TH14-06-0484-84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"10.1160\/TH14-06-0484-85","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S24752"},{"key":"10.1160\/TH14-06-0484-86","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.879439"},{"key":"10.1160\/TH14-06-0484-87","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.01.001"},{"key":"10.1160\/TH14-06-0484-88","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-08-0579"},{"key":"10.1160\/TH14-06-0484-89","doi-asserted-by":"publisher","DOI":"10.2165\/11591590-000000000-00000"},{"key":"10.1160\/TH14-06-0484-90","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.07.2686"},{"key":"10.1160\/TH14-06-0484-91","first-page":"S22","volume":"17","author":"Kwong","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1160\/TH14-06-0484-92","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-01-0071"},{"key":"10.1160\/TH14-06-0484-93","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-12-0919"},{"key":"10.1160\/TH14-06-0484-94","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.858634"},{"key":"10.1160\/TH14-06-0484-95","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.09.015"},{"key":"10.1160\/TH14-06-0484-96","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.02.006"},{"key":"10.1160\/TH14-06-0484-97","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1412S3"},{"key":"10.1160\/TH14-06-0484-98","unstructured":"National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Technology appraisal 261. Available at: http:\/\/www.nice.org.uk\/ta261. Accessed August 6, 2014"},{"key":"10.1160\/TH14-06-0484-99","unstructured":"National Institute for Health and Care Excellence. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism; NICE technology appraisal guidance 287. Available at: http:\/\/www.nice.org.uk\/guidance\/TA287. Accessed August 6, 2014"},{"key":"10.1160\/TH14-06-0484-100","unstructured":"National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. Technology appraisal guidance 170. Available at: http:\/\/www.nice.org.uk\/guidance\/TA170. Accessed August 6, 2014"},{"key":"10.1160\/TH14-06-0484-101","unstructured":"National Institute for Health and Clinical Excellence. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. Technology appraisal 245. Available at: http:\/\/www.nice.org.uk\/guidance\/TA245. Accessed August 6, 2014"},{"key":"10.1160\/TH14-06-0484-102","unstructured":"National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal 157. Available at: http:\/\/www.nice.org.uk\/guidance\/TA157. Accessed August 6, 2014"},{"key":"10.1160\/TH14-06-0484-103","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-12-0919"},{"key":"10.1160\/TH14-06-0484-104","unstructured":"http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH14-06-0484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T21:40:23Z","timestamp":1598391623000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH14-06-0484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":104,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2017,11,21]]},"published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1160\/th14-06-0484","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}